Pegylated interferon β£ (PEG IFN-β£) improves sustained virological response rates in chronic hepatitis C, but neither its role in acute hepatitis C nor the biologic basis for its action has been defined. This prospective study assessed the efficacy of PEG IFN-β£ treatment in acute hepatitis C in relat
Hepatic and extrahepatic hepatitis C virus replication in relation to response to interferon therapy
β Scribed by Mohamed G. Saleh; Christopher J. Tibbs; John Koskinas; Leila M. M. B. Pereira; Adrian B. Bomford; Bernard C. Portmann; Ian G. McFarlane; Roger Williams
- Publisher
- John Wiley and Sons
- Year
- 1994
- Tongue
- English
- Weight
- 657 KB
- Volume
- 20
- Category
- Article
- ISSN
- 0270-9139
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
CORRESPONDENCE 1287 tive anions determine the potential for crystal precipi-though the location within the stone is not identified. Thus, their data would seem to confirm our findings tation within bile. Certain disease states predispose and be in conflict with the statement in their letter to supe
To determine the patient-dependent and virusrelated factors that may predict sustained response to interferon-a therapy, we prospectively evaluated 60 consecutive patients with chronic hepatitis C who received a standardized treatment schedule of interferon-a. Twenty-eight patients achieved a long-t
Hepatitis C virus (HCV) appears to circulate in various forms such as native virion, immune complexes, and nucleocapsids during chronic infections. To determine the association of the physicochemical properties of HCV and its response to interferon therapy in patients with chronic hepatitis C, we ex
We read with great interest the article by Stepanova et al. 1 In this report from the United States with 10,582 eligible individuals (1.52% of whom were positive for hepatitis C virus [HCV] antibody [anti-HCV]), the rate of insurance coverage was significantly lower in patients with HCV infection (6
To investigate the relationship between genotypes of hepatitis C virus and response to interferon-a therapy, hepatitis C virus RNA was assayed by polymerase chain reaction with three sets of primers and probes in 70 patients with non-A, non-B chronic hepatitis who received interferon-a. Twenty-four